Montilab Tablet 10 mg

Montilab is a branded medication containing Montelukast Sodium (10 mg), manufactured by Labaid Pharma Ltd. This leukotriene receptor antagonist comes in tablet form and is widely prescribed for asthma prevention, allergic rhinitis, and exercise-induced bronchoconstriction. Priced at ৳17.50 per unit, it offers cost-effective management for chronic respiratory conditions.

Clinically effective, Montilab blocks cysteinyl leukotriene receptors to reduce airway inflammation. It’s indicated for:

• Chronic asthma management
• Seasonal/perennial allergic rhinitis
• Exercise-induced breathing difficulties

Dosage varies by age: adults take 10 mg daily, while children (6 months–14 years) require lower doses. Take tablets orally, preferably at night or 2 hours before exercise.

Storage requires keeping tablets below 30°C in dry conditions. Common side effects include headache and gastrointestinal discomfort. Rare but severe reactions may involve mood changes or liver issues. Use cautiously during pregnancy/lactation. For alternatives, explore Montelukast generics.

Montilab’s pricing structure includes strips (৳175) and packs (৳525 for 30 tablets). Its tablet form ensures easy administration. Always consult doctors for dosage adjustments with interacting drugs like warfarin or NSAIDs. Labaid Pharma maintains strict quality standards for this WHO-recommended therapy.

Adults & 15+ years: 10 mg once daily. Children (6-14 years): 5 mg daily. 6 months-5 years: 4 mg daily. For asthma, take at night; for exercise-induced bronchoconstriction, take 2 hours before activity. May be taken with/without food. Do not extend treatment duration without medical supervision.

Common: Diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection.

Uncommon: Akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders.

Rare: Angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor.

Pregnancy: Category B (No risk in animal studies; human data limited). Lactation: Excreted in milk—use cautiously. Consult doctor for risk-benefit analysis.

Precautions: Monitor for neuropsychiatric symptoms (anxiety, suicidal ideation). Not for acute asthma attacks. Regular liver function tests advised in hepatic disorders.

Special Populations: Use age-specific doses in children. No dose adjustment in elderly/renal/hepatic impairment. Avoid in pregnancy unless benefits outweigh risks.

There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of Montilab and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.